Temporal evolution of gene expression in rat carotid artery following balloon angioplasty

Journal of Cellular Biochemistry

Volumn 101, Issue 2, 2007, Pages 399-410

  Li, Jian Ming ^a   Zhang, Xueqing ^a   Nelson, Peter R ^b   Odgren, Paul R ^a   Nelson, Janice D ^b   Vasiliu, Calin ^a   Park, Jane ^a   Morris, Marvin ^a   Lian, Jane ^a   Cutler, Bruce S ^a   Newburger, Peter E ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Angioplasty; Gene expression; Inflammation; Leukocytes; Lymphocytes; Remodeling; Restenosis; SMC

Indexed keywords

CYTOKINE; HERMES ANTIGEN; PHOSPHOPROTEIN; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CAROTID ARTERY; CAROTID ARTERY INJURY; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; DISEASE COURSE; DNA MICROARRAY; EXTRACELLULAR MATRIX; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; GENE INDUCTION; GENETIC CODE; HELPER CELL; HISTOPATHOLOGY; IN SITU HYBRIDIZATION; INTIMA; MACROMOLECULE; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; RESTENOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANGIOPLASTY, BALLOON; ANIMALS; CAROTID ARTERIES; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HYPERPLASIA; IN SITU HYBRIDIZATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 34247880272     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21190     Document Type: Article

References (47)

1. Alter O, Brown PO, Botstein D. 2000. Singular value decomposition for genome-wide expression data processing and modeling. Proc Natl Acad Sci USA 97:10101-10106.
2. Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, Itoh H, Yokoyama M. 1999. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 100:1494-1498.
3. Challacombe JF, Rechtsteiner A, Gottardo R, Rocha LM, Browne EP, Shenk T, Altherr MR, Brettin TS. 2004. Evaluation of the host transcriptional response to human cytomegalovirus infection. Physiological Genomics 18:51-62.
4. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, Greene WC, Valente AJ. 2006. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-{kappa}B- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 281:15099-15109.
5. Clowes AW, Reidy MA, Clowes MM. 1983. Mechanisms of stenosis after arterial injury. Lab Invest 49:208-215.
6. Conti E, Carrozza C, Capoluongo E, Volpe M, Crea F, Zuppi C, Andreotti F. 2004. Insulin-like growth factor-1 as a vascular protective factor. Circulation 110:2260-2265.
7. De Meyer GR, Bult-H. 1997. Mechanisms of neointima formation-Lessons from experimental models. Vasc Med 2:179-189.
8. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. 2001. Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107:1055-1061.
9. Dibra A, Kastrati A, Mehilli J, Fache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A, Investigators I-DS. 2005. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353:663-670.
10. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. 2002. Morphological predictors of restenosis after coronary stenting in humans. Circulation 105:2974-2980.
11. Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK, Wight TN, Virmani R. 2004. Extracellular matrix changes in stented human coronary arteries. Circulation 110:940-947.
12. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R. 2005. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112:270-278.
13. Geary RL, Nikkari ST, Wagner WD, Williams JK, Adams MR, Dean RH. 1998. Wound healing: A paradigm for lumen narrowing after arterial reconstruction. J Vasc Surg 27:96-106.
14. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. 2004. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5:R80.
15. Guzik TJ, Sadowski J, Kapelak B, Jopek A, Rudzinski P, Pillai R, Korbut R, Channon KM. 2004. Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins. Arterioscler Thromb Vasc Biol 24:1614-1620.
16. He B, Lee AY, Dadfarmay S, You L, Xu Z, Reguart N, Mazieres J, Mikami I, McCormick F, Jablons DM. 2005. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res 65:743-748.
17. Hershey GK. 2003. IL-13 receptors and signaling pathways: An evolving web. J Allergy Clin Immunol 111:677-690.
18. Hiasa K, Ishibashi M, Ohtani K, Inoue S, Zhao Q, Kitamoto S, Sata M, Ichiki T, Takeshita A, Egashira K. 2004. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: Next-generation chemokine therapy for therapeutic neovascularization. Circulation 109:2454-2461.
19. Huang W, La Russa V, Alzoubi A, Schwarzenberger P. 2006. Interleukin-17A: A T-cell-derived growth factor for murine and human mesenchymal stem cells. Stem Cells 24:1512-1518.
20. Isoda K, Nishikawa K, Kamezawa Y, Yoshida M, Kusuhara M, Moroi M, Tada N, Ohsuzu F. 2002. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res 91:77-82.
21. Jain N, Thatte J, Braciale T, Ley K, O'Connell M, Lee JK. 2003. Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics 19:1945-1951.
22. Kipshidze N, Dangas G, Tsapenko M, Moses J, Leon MB, Kutryk M, Serruys P. 2004. Role of the endothelium in modulating neointimal formation: Vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 44:733-739.
23. Kluger Y, Basri R, Chang JT, Gerstein M. 2003. Spectral biclustering of microarray data: Coclustering genes and conditions. Genome Res 13:703-716.
24. Kotani M, Fukuda N, Ando H, Hu WY, Kunimoto S, Saito S, Kanmatsuse K. 2003. Chimeric DNA-RNA hammerhead ribozyme targeting PDGF A-chain mRNA specifically inhibits neointima formation in rat carotid artery after balloon injury. Cardiovasc Res 57:265-276.
25. Leask A, Abraham DJ. 2004. TGF-beta signaling and the fibrotic response. FASEB J 18:816-827.
26. Levy SB, Muldowney JA III. 2002. Microarray analysis of neointima: Flowing toward a clear future. Arterioscler Thromb Vasc Biol 22:1946-1947.
27. Li C, Wong WH. 2001. Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci USA 98:31-36.
28. Li JM, Singh MJ, Itani M, Vasiliu C, Hendricks G, Baker SP, Hale JE, Rohrer MJ, Cutler BS, Nelson PR. 2004. Recombinant human thrombomodulin inhibits arterial neointimal hyperplasia after balloon injury. J Vasc Surg 39:1074-1083.
29. Liuzzo JP, Ambrose JA, Coppola JT. 2005. Sirolimus- and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization. J Invasive Cardiol 17:497-502.
30. Lucchesi PA. 2004. Rapamycin plays a new role as differentiator of vascular smooth muscle phenotype. focus on "The mTOR/p70 S6K1 pathway regulates vascular smooth muscle differentiation". Am J Physiol-Cell Physiol 286:C480-C481.
31. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A. 2001. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104:1598-1603.
32. Marks SC Jr, Lundmark C, Wurtz T, Odgren PR, MacKay CA, Mason-Savas A, Popoff SN. 1999. Facial development and type III collagen RNA expression: Concurrent repression in the osteopetrotic (Toothless, tl) rat and rescue after treatment with colony-stimulating factor-1. Dev Dyn 215:117-125.
33. Muni NI, Gross TP. 2004. Problems with drug-eluting coronary stents-the FDA perspective. N Engl J Med 351:1593-1595.
34. Nakatani M, Takeyama Y, Shibata M, Yorozuya M, Suzuki H, Koba S, Katagiri T. 2003. Mechanisms of restenosis after coronary intervention: Difference between plain old balloon angioplasty and stenting. Cardiovascular Pathology 12:40-48.
35. Odgren PR, Gartland A, MacKay CA. 2003. Production of high-activity digoxigenin-labeled riboprobes for in situ hybridization using the AmpliScribe™ T7 high yield transcription kit. Epi Forum 10:6-7.
36. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:1133-1141.
37. Schober A, Weber C. 2005. Mechanisms of monocyte recruitment in vascular repair after injury. Antioxidants Redox Signaling 7:1249-1257.
38. Schober A, Zernecke A, Liehn EA, von Hundelshausen P, Knarren S, Kuziel WA, Weber C. 2004. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Circ Res 95:1125-1133.
39. Tabibiazar R, Wagner RA, Ashley EA, King JY, Ferrara R, Spin JM, Sanan DA, Narasimhan B, Tibshirani R, Tsao PS, Efron B, Quertermous T. 2005. Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. Physiol Genomics 22:213-226.
40. van der Hoeven BL, Pires NM, Warda HM, Oemrawsingh PV, van Vlijmen BJ, Quax PH, Schalij MJ, van der Wall EE, Jukema JW. 2005. Drug-eluting stents: Results, promises and problems. Int J Cardiol 99:9-17.
41. Wainwright CL, Miller AM, Wadsworth RM. 2001. Inflammation as a key event in the development of neointima following vascular balloon injury. Clin Exp Pharmacol Physiol 28:891-895.
42. Weigert J, Neumeier M, Schaffler A, Fleck M, Scholmerich J, Schutz C, Buechler C. 2005. The adiponectin paralog CORS-26 has anti-inflammatory properties and is produced by human monocytic cells. FEBS Lett 579:5565-5570.
43. Welt FG, Rogers C. 2002. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 22:1769-1776.
44. Yamagami H, Kitagawa K, Hoshi T, Furukado S, Hougaku H, Nagai Y, Hori M. 2005. Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol 25:1458-1462.
45. Zhou JS, Friend DS, Lee DM, Li L, Austen KF, Katz HR, 2005. gp49B1 deficiency is associated with increases in cytokine and chemokine production and severity of proliferative synovitis induced by anti-type II collagen mAb. Eur J Immunol 35:1530-1538.
46. Zohlnhofer D, Klein CA, Richter T, Brandl R, Murr A, Nuhrenberg T, Schomig A, Baeuerle PA, Neumann FJ. 2001a. Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation. Circulation 103:1396-1402.
47. Zohlnhofer D, Richter T, Neumann F, Nuhrenberg T, Wessely R, Brandi R, Murr A, Klein CA, Baeuerle PA. 2001b. Transcriptome analysis reveals a role of interferon-gamma in human neointima formation. Mol Cell 7:1059-1069.